Axogen/$AXGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Axogen
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
- Ticker
- $AXGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 622
- Headquarters
- Alachua, United States
- Website
- www.axogeninc.com
Axogen Metrics
BasicAdvanced
$2.2B
-
-$0.68
1.16
-
Price and volume
Market cap
$2.2B
Beta
1.16
52-week high
$52.91
52-week low
$15.27
Average daily volume
1.4M
Financial strength
Current ratio
6.597
Quick ratio
4.792
Long term debt to equity
0.071
Total debt to equity
0.078
Interest coverage (TTM)
-3.08%
Profitability
EBITDA (TTM)
-5.968
Gross margin (TTM)
74.56%
Net profit margin (TTM)
-13.36%
Operating margin (TTM)
-5.12%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-3.15%
Return on equity (TTM)
-18.21%
Valuation
Price to revenue (TTM)
7.318
Price to book
7.77
Price to tangible book (TTM)
8.01
Price to free cash flow (TTM)
282.338
Free cash flow yield (TTM)
0.35%
Free cash flow per share (TTM)
0.131
Growth
Revenue change (TTM)
23.57%
Earnings per share change (TTM)
558.36%
3-year revenue growth (CAGR)
19.30%
10-year revenue growth (CAGR)
21.98%
3-year earnings per share growth (CAGR)
7.04%
10-year earnings per share growth (CAGR)
4.24%
What the Analysts think about Axogen
Analyst ratings (Buy, Hold, Sell) for Axogen stock.
Analyst projections of the future price of Axogen stock.
Bulls say / Bears say
Second-quarter revenue rose 23.1%, and Axogen raised its 2026 revenue-growth target to at least 24%, or $279 million. Management also expects positive free cash flow for the year, signalling confidence that growth can begin to support cash generation. (Axogen, Inc.)
Access and reimbursement are improving: Cigna and Elevance issued positive coverage decisions, while a new CMS procedure code lifted Avance facility reimbursement by 40% for hospital outpatient procedures and 35% for ambulatory surgery centres. Better coverage and payment may make treatment easier for providers to offer. (Axogen, Inc.)
The planned BioCircuit acquisition would add NerveTape, which Axogen describes as the first FDA-cleared sutureless device for nerve repair. Management expects the deal to contribute about $34 million in 2027 revenue, creating a potential new growth stream if the transaction closes and targets are achieved. (U.S. Securities and Exchange Commission)
Strong sales have not yet translated into steady GAAP profitability: Axogen reported a $1.5 million second-quarter net loss, versus net income a year earlier, and gross margin fell to 72.7% from 74.2%. Continued margin pressure could make the growth story less valuable to shareholders. (Axogen, Inc.)
Axogen’s planned public share offering to help fund the BioCircuit deal would dilute existing shareholders. The acquisition therefore adds a financing cost even if its expected revenue contribution is delivered. (Investing.com)
Axogen says it relies heavily on its Ohio processing centre and Dayton facility, and that a prolonged loss of either site could harm the business. This leaves a material operational vulnerability alongside the company’s growth plans. (Axogen, Inc.)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Axogen Financial Performance
Revenues and expenses
Axogen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Axogen News
AllArticlesVideos
Funds containing Axogen
AllUSDEURGBP
Fund name | Fund size | $AXGN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.18% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.18% |
iShares Healthcare Innovation£DRDR | £1B | 0.18% |
iShares Ageing Population$AGED | $953M | 0.16% |
iShares Ageing Population€AGED | €822M | 0.16% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.